Advancing Treg-Modulating Therapies in Dermatological Conditions Through Clinical Validation

2:30 pm - Wednesday 24th March 2027

  • Evaluating clinical trial strategies for Treg-directed and Treg-modulating therapies in dermatological autoimmune diseases to demonstrate meaningful patient benefit
  • Leveraging accessible tissue biopsies to generate mechanistic insights and support pharmacodynamic biomarker development for clinical decision-making
  • Defining clinical differentiation through durability, biomarker assessment, and patient selection strategies to strengthen the path toward broader adoption and partnership interest

Speakers:

Scientist, Director Business Development
HCW Biologics Inc.